文献速递银屑病与炎症性皮肤病

SPECTREM IIIb期试验第16周:古塞奇尤单抗治疗低体表面积伴高影响部位中重度银屑病

SPECTREM phase IIIb clinical trial results through week 16: guselkumab efficacy and safety for the treatment of low body surface area, moderate psoriasis with high-impact site involvement.
PubMed 文献 · Br J Dermatol · 2026-01-01

SPECTREM是一项IIIb期随机安慰剂对照试验,纳入338例体表面积2-15%、IGA=3且累及至少一个高影响部位(头皮、面部、生殖器、间擦部位)的斑块状银屑病患者,按2:1随机接受古塞奇尤单抗100mg或安慰剂。第16周时,古塞奇尤单抗在IGA 0/1、IGA 0、PASI 90、PASI 100及BSA/PASI改善百分比等主要和次要终点均显著优于安慰剂(所有P<0.001),且安全性与安慰剂相似。

要点

  • 古塞奇尤单抗第16周IGA 0/1达74.2%,安慰剂仅12.4%(P<0.001)。
  • 高影响部位(头皮、面部、生殖器、间擦)的IGA/PGA 0/1应答率古塞奇尤单抗组均显著高于安慰剂。
  • 不良事件发生率古塞奇尤单抗组37.8%、安慰剂组39.8%,未发现新安全性信号。

核心结论

  • 第16周时,古塞奇尤单抗对低体表面积(2-15%)、中度斑块状银屑病且累及高影响部位的患者有效且耐受性良好。

研究设计与样本

  • SPECTREM为IIIb期随机、安慰剂对照研究(NCT06039189),纳入338例低BSA(2-15%)、IGA=3且累及至少一个高影响部位的斑块状银屑病患者,按2:1随机分配至古塞奇尤单抗100mg组(n=225)或安慰剂组(n=113),第0、4周给药后每8周一次。

主要发现

  • 第16周,古塞奇尤单抗组与安慰剂组达到IGA 0/1的比例分别为74.2% vs. 12.4%,IGA 0为40.4% vs. 3.5%,PASI 90为52.9% vs. 6.2%,PASI 100为32.4% vs. 2.7%,所有主要和次要终点均达到(所有P<0.001)。
  • 第16周BSA平均改善百分比古塞奇尤单抗组为80.6%,安慰剂组为6.1%;PASI平均改善百分比分别为82.6% vs. 13.7%。
  • 基线时特定部位IGA/PGA≥3的患者中,古塞奇尤单抗组与安慰剂组达到部位特异性IGA/PGA 0/1的比例分别为:头皮75.0%(114/152) vs. 14.5%(11/76);面部87.8%(79/90) vs. 28.6%(12/42);生殖器78.0%(64/82) vs. 37.5%(15/40);间擦部位86.5%(96/111) vs. 28.8%(15/52)。
  • 古塞奇尤单抗组和安慰剂组分别有37.8%和39.8%的患者发生至少一次不良事件,未发现新的安全性信号。

关键数值与推荐

  • 主要终点为第16周达到IGA 0/1(清除/几乎清除)的受试者比例。
  • 主要次要终点包括第16周达到PASI 90、IGA 0、PASI 100的比例,BSA和PASI相对基线的平均改善百分比,以及基线时特定部位IGA/PGA≥3者达到部位特异性IGA/PGA 0/1的比例。

临床怎么用

  • 对于体表面积低(2-15%)但累及头皮、面部、生殖器或间擦部位的中度银屑病患者,古塞奇尤单抗第16周可提供高比例的皮损清除或几乎清除。
  • 古塞奇尤单抗在高影响部位的疗效支持其用于这类临床研究中常被忽视的患者群体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with psoriasis affecting a low percentage of their body surface area (BSA) are under-represented in clinical studies and may face substantial disease burden if high-impact sites are affected. OBJECTIVES: To evaluate in a phase IIIb randomized placebo-controlled study (SPECTREM; NCT06039189) the efficacy and safety of guselkumab in participants with low BSA (2-15%), moderate [Investigator's Global Assessment (IGA) = 3] plaque psoriasis involving one or more high-impact site (scalp, face, genitals, intertriginous areas). METHODS: Eligible participants were randomized 2 : 1 to receive guselkumab 100 mg or placebo at week 0 and week 4, then every 8 weeks. The primary endpoint was the proportion of participants achieving IGA 0/1 (cleared/minimal) at week 16. Major secondary endpoints included the proportion of participants achieving ≥ 90% improvement in Psoriasis Area and Severity Index (PASI 90), IGA 0 and 100% improvement in PASI (PASI 100); mean percentage improvements from baseline to week 16 in BSA and PASI; and proportions of participants achieving site-specific IGA or Physician's Global Assessment (PGA) 0/1 among those with scalp, facial, genital or intertriginous site-specific IGA/PGA ≥ 3 at baseline. RESULTS: Among the 338 randomized participants (guselkumab, n = 225; placebo, n = 113), mean (SD) baseline BSA was 7.6% (3.7) and PASI was 9.0 (3.8). At week 16, all primary and major secondary endpoints were met, with guselkumab demonstrating superiority vs. placebo (all P < 0.001) in the proportions of participants achieving IGA 0/1 (74.2% vs. 12.4%), IGA 0 (40.4% vs. 3.5%), PASI 90 (52.9% vs. 6.2%) and PASI 100 (32.4% vs. 2.7%), and mean percentage improvement from baseline in BSA (80.6% vs. 6.1%) and PASI (82.6% vs. 13.7%). Site-specific IGA/PGA 0/1 response rates for guselkumab vs. placebo were as follows: scalp 75.0% (n = 114/152) vs. 14.5% (n = 11/76); face 87.8% (n = 79/90) vs. 28.6% (n = 12/42); genital 78.0% (n = 64/82) vs. 37.5% (n = 15/40) and intertriginous 86.5% (n = 96/111) vs. 28.8% (n = 15/52). In the guselkumab and placebo groups, respectively, 37.8% and 39.8% experienced one or more adverse event; no new safety signals were identified. CONCLUSIONS: Through week 16, guselkumab was effective and well tolerated in participants with low BSA, moderate plaque psoriasis with involvement of high-impact sites. Statistically significant improvements across multiple clearance measures, irrespective of baseline BSA, support the effectiveness of guselkumab across a broad range of patients. Psoriasis is a chronic inflammatory skin disease. For most people with psoriasis, less than 10% of their body surface area is affected. They are often treated with medicated creams or ointments that are applied to the skin. However, some people can have psoriasis at ‘high-impact sites’. These high-impact sites include the scalp, the face, the genitals, skin folds and/or the palms of the hands and soles of the feet. These areas can be difficult to treat. Psoriasis in these areas can cause itching and pain. It can have a negative impact on people’s quality of life – just as much as people with psoriasis affecting more body surface area. The International Psoriasis Council recommends that people with psoriasis in high-impact areas should be considered for other medications. The SPECTREM clinical trial studied how well a medicine called guselkumab worked in 338 people with psoriasis. The participants had psoriasis involving 2% to 15% of their body surface area and it affected at least one high-impact body site. Participants received guselkumab or placebo (a ‘dummy’ drug), at trial weeks 0, 4 and 12. Improvements were compared at week 16. At week 16, almost three-quarters of people who received guselkumab had no or minimal psoriasis. This compared with just over a tenth of people who received placebo. More than 40% of people treated with guselkumab had completely clear skin. When we measured the effects of guselkumab in people with psoriasis at high-impact sites, approximately 8 in 10 people had no or minimal psoriasis at week 16. The types and rates of side effects we observed in people receiving guselkumab were similar to placebo. The most common side effect was the common cold. Our results show that clear or almost clear skin in all body regions was achieved in most people with psoriasis after three doses of guselkumab. In conclusion, guselkumab is safe and effective for treating psoriasis.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Stein Gold L, Gottlieb AB, Armstrong AW, et al. SPECTREM phase IIIb clinical trial results through week 16: guselkumab efficacy and safety for the treatment of low body surface area, moderate psoriasis with high-impact site involvement. Br J Dermatol. 2026. PMID: 40875818. doi:10.1093/bjd/ljaf327

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。